Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 26, 2007 Rich Duprey	Foolish Forecast: Getting Indigestion With ViroPharma The small-cap pharmaceutical will report its fourth-quarter 2006 financial results shortly. Investors, here is what you can expect to see.
The Motley Fool November 24, 2010 Sean Williams	ViroPharma: Bargain or Value Trap? Generic competition and production issues are major red flags.
The Motley Fool November 21, 2007 Brian Lawler	Black Friday Bargain Stock: ViroPharma Is ViroPharma a good value right now? With competition worries out of the way, and a strong and growing cash flow, it won't take much success for value investors to be rewarded.
The Motley Fool November 3, 2006 Brian Lawler	Nothing's Wrong With ViroPharma Despite potential generic competition on the horizon, the company is going strong. Vancocin's fate will determine how well shares of ViroPharma perform in the near future.
The Motley Fool February 28, 2008 Brian Lawler	ViroPharma in Check Sales of its antibiotic are slowing down, but there is a promising drug in its pipeline.
The Motley Fool August 5, 2009 Brian Orelli	The Cash Cow Is Out of Milk ViroPharma has milked its antibiotic Vancocin, which it bought from Eli Lilly in 2004, pretty well, but it looks like the cash cow is finally running dry.
The Motley Fool January 9, 2007 Brian Lawler	ViroPharma's Healthy Sales Guidance The coming year looks like another strong one for the drug developer. This small-cap pharmaceutical stock is worth taking a look at just for its cheap valuation.
The Motley Fool May 29, 2009 Brian Orelli	The Clouds Are Parting The Food and Drug Administration has scheduled an advisory committee meeting for Aug. 4 to get input on whether the agency should approve generic versions of ViroPharma's antibiotic, Vancocin.
The Motley Fool August 6, 2007 Brian Lawler	Don't Discount ViroPharma The exciting biopharma announces its second-quarter financial results. Considering that its lead drug is highly profitable and has two strong pipeline candidates in development, shares of ViroPharma don't look expensive.
The Motley Fool September 29, 2006 Brian Lawler	The Long Road Ahead for ViroPharma Faced with the threat of generic competition, the company focuses its efforts on a new drug. ViroPharma investors should watch intently.
The Motley Fool April 30, 2008 Brian Lawler	ViroPharma: Risky and Exciting Solid lead drug, meet promising pipeline candidate.
The Motley Fool February 9, 2009 Brian Orelli	ViroPharma Cut in Half ViroPharma's phase 3 drug, maribavir, failed to show an effect in reducing cytomegalovirus (CMV) disease in stem cell transplant patients, and the stock gets axed in half.
The Motley Fool May 7, 2007 Brian Lawler	ViroPharma Victorious A strong first quarter helps the pharmaceutical storm into 2007. Investors, take note.
The Motley Fool July 9, 2008 Brian Lawler	ViroPharma Makes Its Case Rather than taking the more traditional route, ViroPharma has taken steps to try to make it significantly harder than normal for a generic-drug maker to attack its lead drug, Vancocin.
The Motley Fool October 30, 2007 Brian Lawler	ViroPharma Gets No Respect The drugmaker announces third-quarter results; sales of its only marketed drug, antibiotic treatment Vancocin, fell due to a higher level of wholesaler stocking. Investors, take note.
The Motley Fool March 2, 2007 Brian Lawler	Veering ViroPharma The drugmaker announces healthier fourth-quarter financial results. But investors take note: ViroPharma's product could have a formidable competitor on the market in 2008.
The Motley Fool April 4, 2011 Brian Orelli	Anti-Infective, Very Effective The FDA seems to like Optimer's new antibiotic.
The Motley Fool July 16, 2008 Brian Lawler	A Big Move From ViroPharma ViroPharma picks up an asset that's more than half its size.
The Motley Fool May 31, 2011 Brian Orelli	Pay Attention, Biotech Investors Competitors and partners can't be ignored.
The Motley Fool November 30, 2009 Brian Orelli	The FDA Moves the Goalposts The FDA sends a complete response letter to Theravance about its antibiotic Vibativ, which it's trying to get approved for treating patients with nosocomial pneumonia.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool May 31, 2011 Brian Orelli	Down! Up! Which Way Will Optimer Go Next? Long-term prospects look good.
Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
The Motley Fool March 25, 2009 Brian Orelli	Wyeth: Now Approved to Kill More Bugs! Wyeth's antibiotic gets approved for another indication.
The Motley Fool August 31, 2011 Brian Orelli	Shire Enters a Crowded Market Last week, the FDA approved Shire Pharmaceuticals' Firazyr to treat a rare genetic disease.
The Motley Fool November 27, 2009 Brian Orelli	Biotech Bargains for Your Portfolio Everyone is looking for bargains this time of year. That includes pharmaceutical giants looking to pick up some biotechs on the discount rack, and investors trying to get there first.
BusinessWeek November 3, 2003 Diane Brady	Biotech: Teva's Next Triumph? The Israeli maker of generics wants a piece of the fast-growing bio-drug market.
The Motley Fool April 6, 2011 Brian Orelli	Killing Bacteria With the Help of a Friend Optimer Pharmaceuticals has signed up Cubist Pharmaceuticals as a marketing partner for at least the next two years.
The Motley Fool October 9, 2006 Brian Lawler	The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field.
The Motley Fool May 26, 2009 Brian Orelli	Will the FDA Approve These Drugs? Plenty of Prescription Drug User Fee Act dates are right around the corner. Read on to see which pharma companies may be affected.
The Motley Fool October 22, 2010 Brian Orelli	No Swelling Sales Here ViroPharma saw its stellar launch of hereditary angioedema treatment Cinryze come to a standstill until it could scale up manufacturing further.
The Motley Fool September 27, 2007 Brian Lawler	ViroPharma's Good Bad News The prospects for ViroPharma's HCV-796 darkened significantly after the company reported troubling clinical results, however, there's still hope for the compound. Investors, take note.
The Motley Fool April 17, 2008 Brian Lawler	The End for (Another) Hepatitis C Drug Candidate ViroPharma stops development of its compound after data showed it may hurt the liver.
The Motley Fool January 28, 2011 Brian Orelli	Value Investing, Biotech Style Biotech investors should regard every binary event as a varying degree of confidence in a positive or negative result.
The Motley Fool August 8, 2006 Stephen D. Simpson	Nothing Generic About Teva's Performance Once again, buying this this Israeli generics giant on dips returns a tidy profit.
Pharmaceutical Executive October 1, 2011	30 Years of Pharma: Perspective in Numbers, Part 3 Top 10 generics companies.
The Motley Fool May 25, 2011 Brian Orelli	Optimer's Upcoming FDA Decision: Memorable or Memorial? We'll know on Memorial Day, plus or minus a few days.
The Motley Fool June 1, 2005 Rich Duprey	Able Labs Disabled The generic drug maker recalls its entire inventory over quality concerns. Its stock price cratered 75% the day after the announcement and has since fallen another 30% since then.
Pharmaceutical Executive May 1, 2011 John F. Brenner	Expanded Liability for Generic, Brand Manufacturers Ahead? To what extent are generics companies obligated by law to request labeling changes with FDA?
The Motley Fool August 10, 2007 Brian Lawler	ViroPharma Whacked by Data Shares of ViroPharma fall after safety issues come to light with one of its drugs. A phase 2 study of their hepatitis C antiviral medication has been halted, with only a slim chance of starting up again.
Managed Care February 2008 Martin Sipkoff	FDA Approach to Generics May Be a Mixed Blessing A recently announced initiative is supposed to speed approval of generic drugs, but does it address some fundamental flaws in the approval process?
Managed Care September 2007 Martin Sipkoff	Patent Law Rulings Work in Favor of Generics Thanks to recent Supreme Court rulings, manufacturers of generic drugs are in a good position to continue expansion of their market share.
The Motley Fool June 13, 2007 Brian Lawler	ViroPharma Is on Its Way ViroPharma completes preliminary enrollment in a study of one of its drug candidates. Investors, take note.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer's Generic Growth, With a Side of Sashimi A move into Japan isn't a bad idea, but it isn't going to save the company either.
The Motley Fool June 26, 2006 Stephen D. Simpson	Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note.
The Motley Fool January 20, 2005 Stephen D. Simpson	Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error.
Bio-IT World September 16, 2004 Paul King	Growing Gains When it comes to information technology requirements, the biotech industry is unlike any other. A key enabler of efficient and effective growth is the adoption of IT strategies specific to each of four key stages.
Fast Company February 2009 Elizabeth Svoboda	Wyeth's Multibillion-dollar Biotech Bet Drugmaker Wyeth bet billions on biotech, transforming its culture and boosting profits.
Chemistry World May 21, 2009 Matt Wilkinson	Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets.
The Motley Fool January 28, 2005 Karl Thiel	Will the FDA Kill Biotech? Proposed legislation could spell changes across the pharmaceutical world. Investors are right to be nervous.